The Adverse Drug Reactions from Patient Reports in Social Media Project: Five Major Challenges to Overcome to Operationalize Analysis and Efficiently Support Pharmacovigilance Process

Bousquet, Cédric; Dahamna, Badisse; Guillemin-Lanne, Sylvie; Darmoni, Stéfan Jacques; Faviez, Carole; Huot, Charles; Katsahian, Sandrine; Leroux, Vincent; Pereira, Suzanne; Richard, Christophe; Schück, Stéphane; Souvignet, Julien; Louët, Agnés Lillo‐Le; Texier, Nathalie

doi:10.2196/resprot.6463

Cited by 26 publications

(21 citation statements)

References 30 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Educating health professionals is widely considered a good method to improve reporting, but partnerships with patients’ associations and use of electronic tools (e.g. user-friendly, freely accessible web platforms for reporting ADRs instead of paper forms such as the yellow cards) can also help [ 38 , 39 ].…”

Section: Resultsmentioning

confidence: 99%

Pharmacovigilance in oncology

et al. 2018

View full text Add to dashboard Cite

Background Side effects of cancer therapy are one of the most important issues faced by cancer patients during their illness. Pharmacovigilance, namely the science and activities aimed at monitoring the safety of drugs, is particularly important in oncology, due to the intrinsic biologic toxicity of antineoplastic agents, their narrow therapeutic windows, and the high doses and rigid timing of treatment regimens. Aim of the review To identify the main issues in carrying out an effective pharmacovigilance activity in oncology. Method We searched PubMed for articles about pharmacovigilance in relation to chemotherapy, radiotherapy and targeted therapy for cancer, using MeSH terms and text words. We also searched Embase, CINAHL, Scopus, Micromedex, the Cochrane Library, two pharmacovigilance databases and the gray literature for articles published in 2012–2018. Overall, 137 articles were considered potentially relevant and were critically appraised independently by two authors, leading to the inclusion of 44 relevant studies, guidelines and reviews. Another 10 important research reports were included in the review. Results Eight critical issues of pharmacovigilance in oncology were identified. These issues pertain to: terminology; range of side effects; targeted therapy and immunotherapy; chemoradiotherapy; generic drugs and biosimilars; drug interactions, pharmacogenetics and polypharmacy; special patient categories; and under-reporting of ADRs. Conclusion The importance of pharmacovigilance in oncology must be highlighted with every effort, to improve safety and offer cancer patients every possible help to improve their quality of life during such a critical period of their lives.Electronic supplementary materialThe online version of this article (10.1007/s11096-018-0706-9) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 99%

Pharmacovigilance in oncology

et al. 2018

View full text Add to dashboard Cite

show abstract

“…extraction of data that do not fit the purpose), extraction of data from sources of unknown quality, or without authorisation, etc. The ADR-PRISM project [86] identified five major challenges to the operationalisation of social data for pharmacovigilance, namely: (1) variable quality of information on social media, (2) guarantee of data privacy, (3) response to pharmacovigilance expert expectations, (4) identification of relevant information within web pages and (5) robust and evolutionary architecture.…”

Section: Current Challenges and The Way Forwardmentioning

confidence: 99%

“…The collection of more case data relating to possible causation is needed [120]. Further research is required towards the development of a comprehensive approach to combining evidence from multiple social media, while considering the level of trust in each source [57,86]. To describe the process, Adjeroh et al [121] employ the term signal fusion stating the diversity of social media sources, noise, data redundancy and correlation between sources as its major challenges.…”

Section: Analysis Of Social Datamentioning

confidence: 99%

“…Principal research area [62,63,86,[127][128][129][130]133] New regulatory paradigms for the incorporation of social data into pharmacovigilance systems for de novo signal detection or to complement and enrich primary data sources to better understand the strengths and limitations of social media in post-market safety surveillance and establish best practices [62]. With regard to the four points (key tasks, see Sect.…”

Section: Attributementioning

confidence: 99%

See 1 more Smart Citation

Harnessing social media data for pharmacovigilance: a review of current state of the art, challenges and future directions

Pappa

Stergioulas

2019

Int J Data Sci Anal

View full text Add to dashboard Cite

The ever-increasing supply of information combined with the growing knowledge elicitation capabilities of key emerging technologies presents pharmacovigilance with enormous opportunities. Currently, safety monitoring is expanding its evidence base, moving beyond traditional approaches towards sophisticated methods that can identify possible safety signals from multiple information sources, both structured and unstructured. In this context, health information posted online by patients represents a potentially valuable, yet currently left largely unexploited source of post-market safety data that could supplement data from traditional sources of drug safety information. As the use of social media data for pharmacovigilance is still in its infancy, the present paper explores the state of the art in the application of social data to adverse drug reaction detection; provides a thorough review of existing work in the field, highlighting important research efforts and achievements; and finally, discusses the current challenges and promising avenues for future work. Following a literature review methodology, a critical appraisal was conducted of carefully selected work on the use of social data in post-market surveillance, as presented in the recent scientific literature. Out of a sample of more than 1300 articles, which was the result of the literature search, the final selection of articles was made based on their relevance to the applications of social networking sites (SNS) to pharmacovigilance, and a thorough review of this corpus was completed with a total of 100 articles reviewed. The main contributions of this review include the mapping and systematisation of the current knowledge in the field by drawing comparisons of different approaches, types of social data and of relevant sources currently used in the field, and by developing new classifications of social data sources and taxonomies for social data for use in pharmacovigilance, as well as the identification of key challenges and the extraction of new insights in terms of potential for practical applications and future research directions in the area of pharmacovigilance. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

show abstract

“…Artificial intelligence may be able to make this process automatic. The use of social media, especially by patients, to post information on drug events is now a major source of data [31]. Controversy as to the ethical utilization of these sources and other "big data" may limit access.…”

mentioning

confidence: 99%